Difference between revisions of "Megestrol (Megace)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
*[[Renal cell carcinoma - historical|Renal cell carcinoma]] | *[[Renal cell carcinoma - historical|Renal cell carcinoma]] | ||
| + | ==History of changes in EMA indication== | ||
| + | *1971-08-18: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' SC10363 | *'''Code name:''' SC10363 | ||
| Line 23: | Line 25: | ||
[[Category:FDA approved in 1971]] | [[Category:FDA approved in 1971]] | ||
| + | [[Category:EMA approved in 1971]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Revision as of 23:15, 13 June 2023
Diseases for which it is used
Diseases for which it was used
History of changes in EMA indication
- 1971-08-18: EURD
Also known as
- Code name: SC10363
- Generic name: megestrol acetate
- Brand name: Maygace, Megace, Megestat, Megestil, Niagestin, Ovaban, Pallace